Publications

manuscript banner_1

Sengupta S, Nagalingam A, Bonner MY, Kuppusamy P, Lanoue D, Shriver M, Muniraj N, Cho S, Begum A, Matsui W, Sukumar S, Marignani PA, Arbiser JL, Saxena NK and Sharma D. (2017) Activation of tumour suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic stat3. Oncogene June 5  Oncogene

Vila-Leahey A, Oldford S, Marignani PA, Haidl I and Marshall J (2016) Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. OncoImmunology. 10;5(7):e1151591 OncoImmunology

Nahta,R., Andrade-Vieira, R., Marignani, PA., et al (2015) Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression Carcinogenesis 36 (Suppl 1): S2-S18. Carcinogenesis

Goodson WH, Lowe L, Andrade-Vieira, R, Marignani PA, et al.  (2015) Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead Carcinogenesis 36 (Suppl 1):S254-296. Carcinogenesis

Andrade-Vieira, R, Bentley, H, Goguen, D. Bowen C & Marignani, PA. (2014)  Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss. Oncotarget 5(24): 12738-12752. Oncotarget

Andrade-Vieira, R, Han J., and Marignani PA.  (2013) Omega-3 polyunsaturated fatty acid promotes the inhibition of glycolytic enzymes and mTOR signaling by regulating the tumor suppressor LKB1. Cancer Biology and Therapy, 14(11):1050-105. Cancer Biology and Therapy

Andrade-Vieira, R, Xu, Z, Colp, P & Marignani, PA. (2013) Loss of lkb1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. Plos One 8(2) e56567. Plos One

Marignani, PA and Sanchez-Cespedes M. The tumour suppressor role of LKB1 in human cancers. Emerging Signaling Pathways in Tumor Biology 2010:71-94.

Soundararajan R, Sayat R, Robertson GS and Marignani PA. (2009) Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM 10) in cancer cells. Cancer Biology and Therapy 8:2052-2060 Cancer Biology and Therapy

Nath-Sain, S. and Marignani, P. A., (2009) LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Molecular Biology of the Cell 20:2785-2795 Molecular Biology of the Cell

Arora, P. D., Marignani, P. A., and McCulloch, C. A., (2008) Collagen phagocytosis is regulated by guanine nucleotide exchange factor Vav2. Am J Physiol Cell Physiol. 295(1):C130-137. American J Physiology

Marignani, P. A., Scott, K. D., Bagnulo, R., Stella, A., Guanti, G., Simone, C., and Resta, N., (2007) Novel splice isoforms of STRADα differentially affect LKB1 activity, complex assembly and sub-cellular localization. Cancer Biology and Therapy 6(9):1627-1631. Cancer Biology and Therapy

Scott, K. D., Nath-Sain, S., Agnew, M. D. and Marignani, P. A., (2007) LKB1 catalytically deficient mutants enhance cyclin D1 expression. Cancer Research 67(12):5622-5627. Cancer Research

Marignani, P. A., (2005) LKB1, the multi-tasking tumour suppressor kinase. Journal of Clinical Pathology 58:15-19. J Clinical Pathology

Scheid, M., Marignani, P. A., and Woodgett, J., (2002) Multiple Phosphoinositide-3-kinase dependent steps in the activation of protein kinase B. Molecular and Cellular Biology 22:6247-6260. Molecular and Cellular Biology

Marignani, P. A., Kanai, F., and Carpenter, C. L., (2001) LKB1 associates with Brg1 and is necessary for Brg1 induced growth arrest. Journal of Biological Chemistry 276:32425-32418. Journal of Biological Chemistry

Marignani, P. A. and Carpenter, C. L., (2001) Vav2 is required for cell spreading. Journal of Cell Biology 154:177-186. Journal of Cell Biology

Ohashi, M., Kanai, F., Tateishi, K., Taniguchi, H., Marignani, P. A., Yoshida, Y., Shiratori, Y., Hamada, H., and Omata, H., (2001) Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. BBRC 282:529-535. BBRC

Kanai, F., Marignani, P. A., Sarbassova, D., Yagi, R., Hall, R. A., Donowitz, M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L. C., and Yaffe, M. B., (2000) TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. Embo J. 19:6778-6791. EMBO J

Kanai, F., Ohashi, M., Marignani, P.A., Shiratori, Y., Hamada, H., and Omata, M., (2000) Adenovirus-mediated drug-sensitivity gene therapy for hepatocellular carcinoma. Methods Mol Med. 45:257-269. Methods Molecular Medicine

Nishikawa, K., Toker, A., Wong, K., Marignani, P. A., Johannes, F. J., and Cantley, L. C., (1998) Association of protein kinase Cmu with type II phosphatidylinositol 4-kinase and type I phosphatidyl-4-phosphate 5-kinase. Journal of Biological Chemistry 273:23126-23133. JBC

Sebaldt RJ and Marignani, P. A., (1997) Diradylglycerol formation is altered by n-3 highly unsaturated fatty acids, with differences between eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. Adv Exp Med Biol. 400:937-945.

Marignani, P. A. and Sebaldt, R. J., (1996) The formation of diradylglycerol molecular species in murine peritoneal macrophages varies dose-dependently with purified eicosapentaenoic and docosahexanoic ethyl esters. Journal of Nutrition 126:2738-2745.

Marignani, P. A., Epand, R. M., and Sebaldt, R. J., (1996) Acyl chain dependence of diacylglycerol activation of protein kinase C activity in vitro. Biochemical and Biophysical Research Communication 225:469-473.

Marignani, P. A. and Sebaldt, R. J., (1996) n-3 polyunsaturated fatty acid-induced changes in the molecular species composition of diradylglycerol in murine peritoneal macrophages remain stable during incubation ex vivo. Lipids 31:771-776.

Marignani, P. A. and Sebaldt, R. J., (1995) Formation of second messenger diradylglycerol in murine peritoneal macrophages is altered after in vivo (n-3) polyunsaturated fatty acid supplementation. J Nutr. 125(12):3030-3040.